Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Yan Xing,Nancy U. Lin,Matthew A. Maurer,Huiqin Chen,Armeen Mahvash,Aysegul Sahin,Argun Akcakanat,Yisheng Li,Vandana Abramson,Jennifer Litton,Mariana Chavez-MacGregor,Vicente Valero,Sarina A. Piha-Paul,David Hong,Kim-Anh Do,Emily Tarco,Dianna Riall,Agda Karina Eterovic,Gerburg M. Wulf,Lewis C. Cantley,Gordon B. Mills,L. Austin Doyle,Eric Winer,Gabriel N. Hortobagyi,Ana Maria Gonzalez-Angulo,Funda Meric-Bernstam
DOI: https://doi.org/10.1186/s13058-019-1154-8
2019-07-05
Breast Cancer Research
Abstract:<h3 class="Heading">Background</h3><p class="Para">The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in patients with advanced breast cancer who had tumors with PIK3CA/AKT1 mutations and/or PTEN loss/mutation.</p><h3 class="Heading">Methods</h3><p class="Para">The primary endpoint was objective response rate (ORR). Secondary endpoints were 6-month progression-free survival (6 m PFS), predictive and pharmacodynamic markers, safety, and tolerability. Patients had pre-treatment and on-treatment biopsies as well as collection of peripheral blood mononuclear cells (PBMC) and platelet-rich plasma (PRP). Next-generation sequencing, immunohistochemistry, and reverse phase protein arrays (RPPA) were performed.</p><h3 class="Heading">Results</h3><p class="Para">Twenty-seven patients received MK-2206. Eighteen patients were enrolled into the <em class="EmphasisTypeItalic">PIK3CA/AKT1</em> mutation arm (cohort A): 13 had <em class="EmphasisTypeItalic">PIK3CA</em> mutations, four had <em class="EmphasisTypeItalic">AKT1</em> mutations, and one had a <em class="EmphasisTypeItalic">PIK3CA</em> mutation as well as PTEN loss. ORR and 6 m PFS were both 5.6% (1/18), with one patient with HR+ breast cancer and a <em class="EmphasisTypeItalic">PIK3CA</em> E542K mutation experiencing a partial response (on treatment for 36 weeks). Nine patients were enrolled on the PTEN loss/mutation arm (cohort B). ORR was 0% and 6 m PFS was 11% (1/9), observed in a patient with triple-negative breast cancer and PTEN loss. The study was stopped early due to futility. The most common adverse events were fatigue (48%) and rash (44%). On pre-treatment biopsy, <em class="EmphasisTypeItalic">PIK3CA</em> and <em class="EmphasisTypeItalic">AKT1</em> mutation status was concordant with archival tissue testing. However, two patients with PTEN loss based on archival testing had PTEN expression on the pre-treatment biopsy. MK-2206 treatment was associated with a significant decline in pAKT S473 and pAKT T308 and PI3K activation score in PBMC and PRPs, but not in tumor biopsies. By IHC, there was no significant decrease in median pAKT S473 or Ki-67 staining, but a drop was observed in both responders.</p><h3 class="Heading">Conclusions</h3><p class="Para">MK-2206 monotherapy had limited clinical activity in advanced breast cancer patients selected for PIK3CA/AKT1 or PTEN mutations or PTEN loss. This may, in part, be due to inadequate target inhibition at tolerable doses in heavily pre-treated patients with pathway activation, as well as tumor heterogeneity and evolution in markers such as PTEN conferring challenges in patient selection.</p><h3 class="Heading">Trial registration</h3><p class="Para">ClinicalTrials.gov, <span class="ExternalRef"><a href="https://clinicaltrials.gov/ct2/show/NCT01277757"><span class="RefSource">NCT01277757</span></a></span>. Registered 13 January 2011.</p>
oncology